Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Novo Nordisk’s Japan Sales Bounce Back to Hit All-Time High
April 9, 2015
- Hisamitsu Sales Up 4.1% despite Dull Japan Biz, Mohrus Down 8.5%
April 9, 2015
- Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
- Bayer Yakuhin Negotiating with Universities, Institutions for Research Agreements
April 9, 2015
- Merck KGaA, Pfizer to Copromote Xalkori in Japan, US, Europe
April 9, 2015
- Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
- BIKEN, Osaka University Strike License Agreement to Develop Novel Pneumococcal Vaccines
April 8, 2015
- Drug Makers Setting Up Medical Affairs Units Independent of Sales Teams
April 7, 2015
- Mochida Using “Granular Tablets” to Gain Share in Generic Drug Market
April 7, 2015
- Pfizer Japan Rolls Out Japan’s 1st Propecia Generic
April 7, 2015
- Biogen Idec Japan Names Steve Sugino, Former Sanofi Diabetes Head, as President
April 7, 2015
- Xtandi Significantly Prolongs PFS vs. Bicalutamide in US: Astellas
April 6, 2015
- Zelboraf a Promising New Treatment Option for Malignant Melanoma: Dr Yamazaki
April 6, 2015
- Takeda Initiates Voluntary Recall of Liovel Combination Tablets LD
April 6, 2015
- Novartis, PeptiDream Conclude License Deal for Drug Discovery Platform Technology
April 6, 2015
- Eisai, Niigata Univ. Finds Correlation of Cognitive Function with Plasma Desmosterol Levels in Alzheimer’s Disease Patients
April 6, 2015
- Astellas Signs Option Deal with US Cancer Center for Monoclonal Antibody Drug for Acute Myeloid Leukemia
April 6, 2015
- Kaken Licenses Topical Hyperhidrosis Treatment from US Biotech
April 3, 2015
- Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
- Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…